kantar

ASCO 2019 and the future of oncology
Kantar-video-image-myeloma

ASCO 2019 - Kantar reviews multiple myeloma showdown

Day three of ASCO 2019 saw a showdown between two anti-CD38 compounds in multiple myeloma, Janssen's Darzalex and Sanofi's isatuximab. Darzalex showed more positive data in newly-d

ASCO 2019 Live coverage
ASCO-2019-Feature-Banner-840x480-NEW

ASCO 2019 day four

Exclusive live coverage from day four of the American Society of Clinical Oncology's annual meeting in Chicago. • To view all of our coverage from the preeminent cancer event, prod